Thyrocare Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Thyrocare TechnologiesDer Gewinn pro Aktie wird voraussichtlich um 13.6% pro Jahr wachsen.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

13.59%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	24.3%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	11 Jul 2025

Jüngste Aktualisierungen zum künftigen Wachstum

Thyrocare Technologies Limited Just Missed Earnings - But Analysts Have Updated Their Models

Jan 28

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 26

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 04

Recent updates

Thyrocare Technologies' (NSE:THYROCARE) Solid Earnings Have Been Accounted For Conservatively

May 02

After Leaping 26% Thyrocare Technologies Limited (NSE:THYROCARE) Shares Are Not Flying Under The Radar

Apr 26

The Returns On Capital At Thyrocare Technologies (NSE:THYROCARE) Don't Inspire Confidence

Apr 23

Thyrocare Technologies Limited Just Missed Earnings - But Analysts Have Updated Their Models

Jan 28

Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings Are

Oct 31

Thyrocare Technologies Limited (NSE:THYROCARE) Looks Just Right With A 26% Price Jump

Aug 01

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 26

A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)

Jun 12

Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be Difficult

Feb 29

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 04

Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Dec 08

Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 08

Thyrocare Technologies (NSE:THYROCARE) Knows How To Allocate Capital Effectively

Mar 23

Thyrocare Technologies Limited (NSE:THYROCARE) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Mar 02

Gewinn- und Umsatzwachstumsprognosen

NSEI:THYROCARE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2026	8,040	1,288	1,900	1,869	1
3/31/2025	6,874	915	1,464	1,913	N/A
12/31/2024	6,544	877	N/A	N/A	N/A
9/30/2024	6,233	840	1,648	1,873	N/A
6/30/2024	5,939	776	N/A	N/A	N/A
3/31/2024	5,719	708	1,061	1,676	N/A
12/31/2023	5,535	655	N/A	N/A	N/A
9/30/2023	5,468	648	647	1,418	N/A
6/30/2023	5,338	599	N/A	N/A	N/A
3/31/2023	5,267	645	857	1,293	N/A
12/31/2022	5,214	731	N/A	N/A	N/A
9/30/2022	5,108	800	749	1,001	N/A
6/30/2022	5,520	1,423	N/A	N/A	N/A
3/31/2022	5,889	1,761	756	1,134	N/A
12/31/2021	6,051	1,924	N/A	N/A	N/A
9/30/2021	6,260	2,032	1,249	1,642	N/A
6/30/2021	6,030	1,685	N/A	N/A	N/A
3/31/2021	4,946	1,132	880	1,147	N/A
12/31/2020	4,503	741	N/A	N/A	N/A
9/30/2020	4,178	692	789	1,004	N/A
6/30/2020	3,797	612	N/A	N/A	N/A
3/31/2020	4,343	884	1,580	1,679	N/A
12/31/2019	4,384	1,063	N/A	N/A	N/A
9/30/2019	4,289	990	1,305	1,436	N/A
6/30/2019	4,165	892	N/A	N/A	N/A
3/31/2019	4,039	851	601	1,003	N/A
12/31/2018	3,946	939	N/A	N/A	N/A
9/30/2018	3,822	953	N/A	N/A	N/A
6/30/2018	3,663	947	N/A	N/A	N/A
3/31/2018	3,569	933	N/A	1,070	N/A
12/31/2017	3,493	1,117	N/A	N/A	N/A
9/30/2017	3,359	994	N/A	N/A	N/A
6/30/2017	3,258	759	N/A	N/A	N/A
3/31/2017	3,045	428	N/A	896	N/A
12/31/2016	2,843	659	N/A	N/A	N/A
9/30/2016	2,699	601	N/A	N/A	N/A
6/30/2016	2,535	564	N/A	N/A	N/A
3/31/2016	2,411	518	N/A	678	N/A
3/31/2015	1,835	452	N/A	345	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von THYROCARE über der Sparquote liegt (6.7%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von THYROCARE schneller wachsen werden als der Markt Indian

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von THYROCARE in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von THYROCARE schneller wachsen werden als der Markt von Indian.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von THYROCARE schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von THYROCARE in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/07/22 14:28
Aktienkurs zum Tagesende	2025/07/22 00:00
Gewinne	2025/03/31
Jährliche Einnahmen	2025/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Thyrocare Technologies Limited wird von 12 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Alka Katiyar	Batlivala & Karani Securities India Pvt. Ltd.
Rahul Agarwal	CGS International
Kameswari V. S. Chavali	FirstCall Research

Thyrocare Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 19% to ₹1,125

Thyrocare Technologies Limited Just Missed Earnings - But Analysts Have Updated Their Models

Price target increased by 9.1% to ₹903

Price target increased by 8.5% to ₹828

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Recent updates

Upcoming dividend of ₹21.00 per share

Thyrocare Technologies Limited to Report Q1, 2026 Results on Jul 23, 2025

New major risk - Revenue and earnings growth

Price target increased by 19% to ₹1,125

Full year 2025 earnings: EPS exceeds analyst expectations

Thyrocare Technologies Limited, Annual General Meeting, Jul 31, 2025

Thyrocare Technologies' (NSE:THYROCARE) Solid Earnings Have Been Accounted For Conservatively

After Leaping 26% Thyrocare Technologies Limited (NSE:THYROCARE) Shares Are Not Flying Under The Radar

Full year 2025 earnings: EPS exceeds analyst expectations

Thyrocare Technologies Limited Recommends Final Dividend for the Financial Year 2024-25

The Returns On Capital At Thyrocare Technologies (NSE:THYROCARE) Don't Inspire Confidence

Thyrocare Technologies Limited to Report Q4, 2025 Results on Apr 23, 2025

New major risk - Revenue and earnings growth

Thyrocare Technologies Limited Just Missed Earnings - But Analysts Have Updated Their Models

Third quarter 2025 earnings: EPS misses analyst expectations

Thyrocare Technologies Limited Announces Company Secretary and Compliance Officer Changes, Effect from January 31, 2025

Thyrocare Technologies Limited to Report Q3, 2025 Results on Jan 23, 2025

Investor sentiment deteriorates as stock falls 19%

MD, CEO & Chairman recently bought ₹1.1m worth of stock

Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings Are

Price target increased by 9.1% to ₹903

Second quarter 2025 earnings released: EPS: ₹4.99 (vs ₹3.84 in 2Q 2024)

High number of new directors

Thyrocare Technologies Limited to Report Q2, 2025 Results on Oct 23, 2024

Now 23% overvalued after recent price rise

Price target increased by 8.5% to ₹828

Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million.

Thyrocare Technologies Limited Announces Cessation of Mr. Neetin Shivajirao Desai as Independent Director as Well as Member of the Respective Committee(s) of the Board

Now 20% overvalued after recent price rise

Thyrocare Technologies Limited Approves Dividend for the Financial Year 2023-24

Thyrocare Technologies Limited Announces Cessation of Gopalkrishna Shivaram Hegde as Independent Director and as Member / Chairman of the Respective Committee

Now 20% overvalued after recent price rise

Upcoming dividend of ₹18.00 per share

Thyrocare Technologies Limited, Annual General Meeting, Aug 23, 2024

Thyrocare Technologies Limited (NSE:THYROCARE) Looks Just Right With A 26% Price Jump

Investor sentiment improves as stock rises 20%

Thyrocare Technologies Limited (BSE:539871) acquired Diagnostic and pathological services business of Polo Labs Private Limited for INR 42.6 million.

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Now 23% overvalued after recent price rise

First quarter 2025 earnings released: EPS: ₹4.52 (vs ₹3.26 in 1Q 2024)

Thyrocare Technologies Limited to Report Q1, 2025 Results on Jul 23, 2024

Now 23% overvalued after recent price rise

A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)

New major risk - Revenue and earnings growth

Thyrocare Technologies Limited Proposes Final Dividend for the Financial Year 2023-24

Thyrocare Technologies Limited to Report Q4, 2024 Results on May 14, 2024

Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be Difficult

Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Think Health Diagnostic Private Limited.

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.89 in 3Q 2023)

Thyrocare Technologies Limited to Report Q3, 2024 Results on Feb 01, 2024

Price target increased by 7.3% to ₹695

Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its Problems

Second quarter 2024 earnings released: EPS: ₹3.84 (vs ₹3.80 in 2Q 2023)

Thyrocare Technologies Limited to Report Q2, 2024 Results on Oct 31, 2023

MD, CEO & Chairman recently bought ₹4.3m worth of stock

Thyrocare Technologies Limited Appoints Alok Kumar Jagnani as Chief Financial Officer

High number of new directors

Thyrocare Technologies Limited to Report Q1, 2024 Results on Aug 01, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited Accepts Resignation of Sachin Salvi as Chief Financial Officer

Price target decreased by 7.0% to ₹730

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2023 Results on May 23, 2023

Thyrocare Technologies Limited Announces Resignation of Vishwas Kulkarni as an Independent Director

Upcoming dividend of ₹18.00 per share at 3.1% yield

MD, CEO & Director recently bought ₹10m worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations